Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned a consensus rating of "Hold" from the nine ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $9.29.

NMRA has been the subject of a number of analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. HC Wainwright decreased their price objective on Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research report on Thursday, April 10th. William Blair cut Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th. Finally, Bank of America reaffirmed an "underperform" rating and set a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock remained flat at $0.63 during mid-day trading on Friday. The company had a trading volume of 158,895 shares, compared to its average volume of 1,463,729. The firm has a market cap of $102.05 million, a PE ratio of -0.34 and a beta of 2.89. Neumora Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $17.19. The firm's 50 day moving average is $1.25 and its 200-day moving average is $6.42.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09. Research analysts forecast that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the fourth quarter worth approximately $61,000. PNC Financial Services Group Inc. acquired a new stake in Neumora Therapeutics during the fourth quarter worth about $64,000. Quantbot Technologies LP bought a new position in Neumora Therapeutics in the 4th quarter valued at about $92,000. PEAK6 LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at approximately $117,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Neumora Therapeutics during the 4th quarter worth approximately $135,000. Institutional investors own 47.65% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.